Mabpharm opens $195m HK IPO, Hansoh kicks off PDIE
Biopharmaceuticals company Mabpharm launched bookbuilding for its up to HK$1.53bn ($195m) flotation, while Hansoh Pharmaceutical Group set pre-marketing in motion for its Hong Kong listing.
Mabpharm is pre-revenue, taking advantage of the HKEX rule added in April last year that allows such biotechnology companies to list. It recorded losses of Rmb149.8m ($21.7m) in 2018 and Rmb47.7m the year before.The company is offering 783.6m shares, which sole sponsor, global co-ordinator and bookrunner CICC is ...
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: email@example.com